Note 1 - Background and Organization	9 Months Ended
Sep. 30, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	NOTE 1. BACKGROUND AND ORGANIZATION Business Operations PLx Pharma Inc., together with its subsidiary PLx Opco Inc., is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. The Company has two Food and Drug Administration (“FDA”) approved products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), which are liquid-filled aspirin capsules for over-the-counter distribution. Impact of COVID-19 Pandemic on Financial Statements On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a “pandemic”, or a worldwide spread of a new disease. Many countries imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses. In response to COVID-19, the Company has not experienced a disruption or delay in the development of VAZALORE. However, the extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company has not experienced any significant negative impact on its September 30, 2021 unaudited consolidated financial statements related to COVID-19.

Note 1 - Background and Organization

9 Months Ended

Sep. 30, 2021

Business Description and Basis of Presentation [Text Block]

NOTE 1. BACKGROUND AND ORGANIZATION

Business Operations

PLx Pharma Inc., together with its subsidiary PLx Opco Inc., is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. The Company has two Food and Drug Administration (“FDA”) approved products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), which are liquid-filled aspirin capsules for over-the-counter distribution.

Impact of COVID-19 Pandemic on Financial Statements

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a “pandemic”, or a worldwide spread of a new disease. Many countries imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses.

In response to COVID-19, the Company has not experienced a disruption or delay in the development of VAZALORE. However, the extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the pandemic. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company has not experienced any significant negative impact on its September 30, 2021 unaudited consolidated financial statements related to COVID-19.